-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182

Benzinga·06/02/2026 14:06:07
Listen to the news
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $165 to $182.